Treatment of ocular cicatricial pemphigoid with sulfasalazine
Treatment of ocular cicatricial pemphigoid with sulfasalazine
复制标题
DOI：
10.1016/s0161-6420(01)00657-1
复制
发表时间：
2001-09-01
期刊：
影响因子：
13.7
通讯作者：
Hoang-Xuan, T
中科院分区：
文献类型：
--
作者：
Doan, S;Lerouic, JF;Hoang-Xuan, T
目的：目的：评价柳氮磺胺吡啶替代氨苯砜治疗眼瘢痕性类天疱疮（OCP）的疗效。设计：回顾性非比较病例系列。参与者：9例经活检证实的OCP患者，既往有氨苯砜相关不良反应口服柳氮磺胺吡啶治疗溶血和胃肠道紊乱。方法：临床数据从患者病历中提取。主要结果测量：患者的症状，眼部炎症，结膜瘢痕，全血细胞计数（包括网织红细胞计数）。结果：在开始柳氮磺胺吡啶治疗，眼部炎症控制，但在所有患者。平均随访12个月（范围：2-35个月）。口服柳氮磺胺吡啶的中位剂量为3 g（范围：1-4 g）。4例患者（45%）单用柳氮磺胺吡啶仍能控制疾病。2例患者（22%）需要连续口服环磷酰胺。3名患者（33%）发生了需要停药的不良反应：2名发生溶血，1名发生胃肠道紊乱。结论：柳氮磺吡啶可能对既往有氨苯砜相关不良反应的OCP患者有用。(C)2001年由美国眼科学会。
Purpose: To assess the outcome of patients with ocular cicatricial pemphigoid (OCP) treated with sulfasalazine as an alternative to dapsone.Design: Retrospective noncomparative case series.Participants: Nine patients with biopsy-proven OCP and previous dapsone-related adverse effects (hemolysis and gastrointestinal disturbances) treated with oral sulfasalazine.Methods: Clinical data were abstracted from patients' medical records.Main Outcome Measures: Patients' symptoms, ocular inflammation, conjunctival scarring, complete blood cell count (including reticulocyte count).Results: At the initiation of sulfasalazine therapy, ocular inflammation was controlled in all patients but one. Mean follow-up was 12 months (range, 2-35 months). Median oral sulfasalazine dosage was 3 g (range, 1-4 g). The disease remained controlled with sulfasalazine alone in four patients (45%). Two patients (22%) required adjunctive oral cyclophosphamide. Adverse effects necessitating drug withdrawal occurred in three patients (33%): hemolysis in two and gastrointestinal disturbances in one.Conclusions: Sulfasalazine may be useful in OCP patients with previous dapsone-related adverse effects. (C) 2001 by the American Academy of Ophthalmology.